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Abstract 
HIV-1 integrase (IN) is an important therapeutic target in the fight against AIDS as its function 
is essential for viral replication. Constant mutations in the HIV-1 genome allow the virus to 
gain resistance to current antiretroviral therapies. Therefore, there is a continued need to 
discover new therapeutic compounds with alternative mechanisms of action. One such 
mechanism is to allosterically inactivate IN through a small molecule inhibitor promoting 
aberrant IN multimerization. IN functions as a tetramer, and if it is multimerized further by a 
compound then IN will no longer be able to carry out its function properly. Another mechanism 
is to interfere with HIV-1 IN binding to its principal cellular interacting partner lens 
epithelium-derived growth factor (LEDGF)/p75. The aim of this study was to utilize novel 
homogeneous time-resolved fluorescence (HTRF)-based assays to identify promising new lead 
compounds and dissect their mechanism of action. Six indole-based compounds were initially 
analyzed by HTRF-based LEDGF/p75-dependent integration assay and compound KF113 with 
an IC50 value of ~ 4.5 µM was selected for further structure-activity relationships studies. 
KF113 exhibited a multimodal mechanism of action as this compound inhibited IN binding to 
LEDGF/p75 as well as induced aberrant IN multimerization. Importantly, KF113 was fully 
active against mutant A128T IN, which confers marked resistance to current quinoline-based 
allosteric IN inhibitors. These results indicate that our innovative HTRF-based assays allow for 
efficient identification of promising inhibitors of HIV-1 IN. Furthermore, the indole-based 
compounds are promising leads for further development and could ultimately lead to the 
discovery of novel anti-HIV-1 drugs.
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Introduction 
Each year in the United States, about 50,000 people are infected with human 
immunodeficiency virus type 1 (HIV-1). In 2012, 1.2 million people were living with HIV-1 in 
the United States (1). In order to halt the progression of HIV to AIDS, highly active antiretroviral 
therapy (HAART) has been used over the past 20 years, and has allowed transformation of this 
once deadly disease into a chronic infection. These drugs are grouped into six different classes, 
including non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse 
transcriptase inhibitors (NRTIs), protease inhibitors (PIs), fusion inhibitors, CCR5 antagonists 
(CCR5s), and integrase strand transfer inhibitors (INSTIs). There are currently over thirty FDA-
approved antiretroviral medicines to treat HIV-1 infection, with some of these being combination 
therapies of two or more of the aforementioned drug classes. The current regimen per 
recommendation of the U.S. Department of Health and Human Services (HHS) often includes 
two NRTIs in combination with an INSTI. Although these current therapies are effective in 
reducing viral loads to undetectable levels within weeks of administration, there remains a large 
number (1 in 8 people, or 12.8% of those infected) of individuals who do not know they are 
infected, and an even larger percentage of people remain untreated. These individuals may allow 
for increased transmission of HIV-1. Furthermore, treated individuals continue to have a lower 
life expectancy than those that are uninfected (2). Taking these factors into consideration, as well 
as the fact that constant mutations in the HIV-1 genome allow the virus to gain resistance to 
current antiretroviral therapies, there is a continued need to discover new therapeutic compounds 
with alternative mechanisms of action. 
HIV-1 integrase (IN) is a multifunctional virally encoded enzyme that catalyzes the 
integration of viral DNA copy of the HIV-1 genome into the human chromosome (Figure 1). IN 
does this in two steps: (1) 3’-processing activity which removes two nucleotides from the 3’-
terminus of each end of viral DNA and (2) the strand transfer of the processed viral DNA into the 
host genome. IN is an important therapeutic target in the fight against AIDS as its function is 
essential for viral replication. The current FDA-approved drugs that target IN include INSTIs 
such as raltegravir, elvitegravir and dolutegravir (3-5). These drugs have high affinity for the 
HIV-1 IN active site. However, mutations of IN in the binding sites of INSTIs have been 
observed in patients, leading to HIV-1 resistance. Therefore, there is a need to research 
alternative mechanisms of HIV-1 inhibition with compounds that utilize allosteric-binding sites. 
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Such mechanisms include modulating protein-protein interactions essential for HIV-1 
integration. Accordingly, we are interested in identifying new compounds that would stabilize 
functionally compromised IN multimers. IN functions as a tetramer, so we are interested in 
compounds that promote aberrant, higher order (greater than the functionally required tetramer) 
multimerization of IN. Another mechanism is to interfere with HIV-1 IN binding to its key 
cellular cofactor LEDGF/p75. This human-chromatin associated protein binds the catalytic core 
domain (CCD) of the IN tetramer and guides the protein to highly active genes in the host 
genome for viral DNA integration. Compounds that can interfere with the binding of these two 
proteins are expected to impair HIV-1 replication (6). To identify such inhibitors we have 
developed innovative homogenous time resolved fluorescence (HTRF)-based methodologies, 
which allow for efficient identification of both types of inhibitors capable of inducing aberrant 
IN multimerization and/or inhibiting IN-LEDGF/p75 binding (7). These improved assays were 
used to characterize a mode of action of recently discovered quinolone-based allosteric IN 
inhibitors (ALLINIs), which are currently undergoing clinical trials (8-10). However, it was also 
reported that quinolone-based ALLINIs exert a low genetic pressure for developing resistant 
strains (6, 9). For example, the A128T substitution in the IN coding region readily emerges in 
cell culture in the presence of quinoline-based ALLINIs. Furthermore, the mutant virus replicates 
at the wild type levels and confers marked resistance to quinolone-based inhibitors (9). 
Therefore, there is a need to develop improved ALLINIs to overcome this problem. In the 
present study we have investigated a new class of indole-based derivatives that potently inhibit 
both the wild type and A128T INs. Therefore, the indole-based compounds synthesized by Dr. 
Fuchs’ group provide promising leads for further development.    
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Figure 1. Schematic for HIV-1 replication cycle provided by aidsinfo.nih.gov. 
Methods 
Homogeneous time-resolved fluorescence (HTRF)-based assays 
The HTRF technique utilizes fluorescence resonance energy transfer (FRET) to measure the 
time-delayed transfer of energy between two fluorophores, a donor (DON) and an acceptor 
(ACE), when in close proximity (Figure 2). A time delay between the system excitation and 
fluorescence measurement allows the signal to be cleared of all non-specific short-lived 
emissions, which in turn enables dissection of true interactions from non-specific fluorescence. 
The application of this approach can be extended to measure a variety of protein-protein and 
protein-nucleic acid interactions, where interacting partners are labeled with DON and ACE 
fluorophores. Therefore, we adapted this technique to monitor IN catalytic activities in the 
presence and absence of its cognate cofactor LEDGF/p75 as well as to evaluate inhibitory 
potencies of the compounds of interest. Furthermore, we have extended the application of the 
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HTRF-based approach to elucidate the ability of small compounds to interfere with IN binding to 
its cognate co-factor LEDGF/p75 and/or induce IN multimerization.   
!  
Figure 2. Schematic for HTRF-based assays.  
HTRF-based LEDGF/p75-dependent integration assay 
This assay measures the IN-catalyzed integration of viral DNA into the target DNA in the 
presence of LEDGF/p75 (Figures 3, 4 and Table 1). The viral DNA is tagged with Cy5 
fluorophore, and the target DNA is biotinylated, allowing it to interact with streptavidin-
europium (SA-EU fluorophore). The integration product is monitored by the intensity of a time-
resolved signal between these two fluorophores. If the compound inhibits any mechanism of 
integration, then there is a corresponding decrease in HTRF signal compared to the control signal 
which is IN that was incubated with diluent DMSO.  
!  6
  !  
Figure 3. Schematic for LEDGF/p75-dependent integration assay. 
Figure 4. Activity enhancement of DNA integration by LEDGF/p75. IN is an Mg2+-dependent 
enzyme. Therefore, EDTA, which chelates Mg2+ ions, inhibits the reaction yielding the HTRF 
signal comparable with the buffer background. 
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Table 1: The protocol for the LEDGF/p75 Dependent Integration assay  
HTRF-based LEDGF/p75-independent 3’-processing assay 
This assay measures the ability of tested compounds to inhibit the 3’-processing catalytic activity 
of IN in the absence of LEDGF/p75 (Figure 5 and Table 2). The viral DNA is tagged with Cy5 
fluorophore on one 3’ end, which is cleaved by IN during the 3’-processing reaction. The 3’ end 
of the complementary DNA stand is biotinylated, allowing it to interact with streptavidin-
europium (SA-EU fluorophore). The 3’-processing reaction is monitored by the change of the 
intensity of a time-resolved signal between these two fluorophores. If IN carries out its catalytic 
function properly, then one of the fluorophores will be cleaved off, resulting in corresponding 
decrease of the HTRF signal. However, if the tested compound inhibits IN 3’-processing activity, 
then the signal remains unchanged. 
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Figure 5. Schematic for the 3’-processing assay 
Parameter Value Description
1 IN Mix 2.5 µl Add to 384-well plate
2 Compound or DMSO or BI-B2 
(positive control)
20 nl Tip transfer and mix
3 Incubation time 30 min. Room temperature. Avoid direct light.
4 DNA substrates + LEDGF/p75 7.5 µl Tip transfer and mix. Avoid direct light.
5 Incubation time 2.5 hr 37°C. Avoid direct light.
6 Streptavidin-EuCryptate Lance 10 µl Tip transfer and mix. Avoid direct light.
7 Incubation time 2.5 hr Room temperature. Avoid direct light.
8 HTRF readout HTRF 
ratio
HTRF signal 
Donor Emission
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Table 2. The protocol for the 3’-processing assay 
HTRF-based IN multimerization assay 
This assay monitors the interaction between two HIV-1 IN proteins: one labeled with an N-
terminal hexa-histidine (6xHis) tag and another labeled with a C-terminal FLAG tag (Figures 6, 
7 and Table 3). Two fluorescent antibodies, anti-6xHis-XL665 and anti-FLAG-EuCryptate (Eu), 
bind to each respective IN tag, allowing fluorescence energy transfer (HTRF signal) upon IN-IN 
interaction. A higher signal indicates that the mixture contains higher order inactive IN 
multimers. If the compound stabilizes functionally compromised IN multimers, then there is a 
corresponding increase in HTRF signal as compared to the background signal of IN that was 
incubated with diluent DMSO.  
The compounds that display activity in the multimerization assay are titrated and run 
through a counterscreen assay, to eliminate false positive hits. Some compounds exhibit long-
lived fluorescence upon energy excitation, leading to an increase in the HTRF signal from a 
source other than the accepter emission. The compounds that exhibit an increase in the HTRF 
signal in the absence of the donor fluorophore are eliminated. The counterscreen is run with the 
same parameters as multimerization assay (Table 3), except that Flag-IN is entirely omitted. 
Parameter Value Description
1 IN Mix 2.5 µl Add to 384-well plate
2 Compound or DMSO or BI-B2 
(positive control)
20 nl Tip transfer and mix
3 Incubation time 60 min. Room temperature. Avoid direct light.
4 DNA substrates 5 µl Tip transfer and mix. Avoid direct light.
5 Incubation time 2.5 hr 37°C. Avoid direct light.
6 Streptavidin-EuCryptate Lance 10 µl Tip transfer and mix. Avoid direct light.
7 Incubation time 2.5 hr Room temperature. Avoid direct light.
8 HTRF readout HTRF 
ratio
HTRF signal 
Donor Emission
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Figure 6. Schematic for HTRF-based IN multimerization assay. 
!  
Figure 7. Schematic to show aberrant IN multimerization induced by ALLINIs.   
Table 3: The protocol for the IN multimerization assay 
Parameter Value Description
1 Flag-IN & His-IN Mix 14 µl Add to 384-well plate
2 Compound or DMSO or 
BI-B2 (positive control)
40 nl Tip transfer and mix
3 Incubation time 3 hr Room temperature
4 Antibody Mix 6 µl Tip transfer and mix
5 Incubation time 2.5 hr Room temperature. Avoid direct light.
6 HTRF readout HTRF 
ratio
HTRF signal 
Donor Emission
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HTRF-based IN-LEDGF/p75 binding assay 
This assay monitors the interaction between HIV-1 IN and LEDGF/p75. HIV-1 IN is labeled 
with an N-terminal hexa-histidine (6xHis) tag and LEDGF/p75 is labeled with a C-terminal 
FLAG tag (Figure 8 and Table 4). Two fluorescent antibodies, anti-6xHis-XL665 and anti-
FLAG-EuCryptate (Eu), bind to each respective tag, allowing fluorescence energy transfer 
(HTRF signal) upon IN-LEDGF interaction. Prospective inhibitors of IN binding to LEDGF/p75 
will lead to a decrease in fluorescent signal in comparison to diluent DMSO.  
!  
Figure 8. Schematic for the HTRF-based IN-LEDGF/p75 binding assay. 
Table 4: The protocol for the IN-LEDGF/p75 binding assay. 
Parameter Value Description
1 His-IN 25 µl Add to 384-well plate
2 Compound or DMSO or 
BI-B2 (positive control)
2 µl Tip transfer and mix
3 Incubation time 1 hr Room temperature
4 LEDGF/p75-Ab Mix 6 µl Tip transfer and mix
5 Incubation time 3 hr 4°C. Avoid direct light.
6 HTRF readout HTRF 
ratio
HTRF signal 
Donor Emission
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Results 
Activities and the mode of action of indole-based compounds. 
I have analyzed six indole-based compounds (Table 5) synthesized by Dr. Fuchs’ laboratory. For 
initial experiments I have used the LEDGF/p75-dependent integration assay because this method 
can capture IN inhibitors with different modes of action. For example, compounds that impair 
either IN catalytic activity, induce aberrant IN multimerization or inhibit IN-LEDGF/p75 binding 
all can be identified by this approach. Comparative analyses of IC50 value for the six indole-
based compounds have revealed KF113 as the most promising lead with an IC50 value of ~ 4.5 
µM (Table 5).  
Table 5. Chemical structures and respective IC50 values of indole-bases compounds evaluated in 
LEDGF/p75-dependent integration assays.  
Chemical structures of the indole-based 
compounds
IC50 for LEDGF/p75-dependent integration 
(µM)
44.1 ± 3.7
32.0 ± 2.5
!  
KF110
N
O
OH
O
FML_1
!  
KF111
N
O
OH
O
FML_2
O
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To dissect the mode action of KF113, I have further analyzed its abilities to inhibit LEDGF/p75-
independent IN 3’-processing activity, IN binding to LEDGF/p75 and/or induce aberrant IN 
multimerization using the above described HTRF-based assays. The results in Figures 9, 10, and 
11 and in summary table 6 show that the indole-based KF113 exhibited a multimodal mechanism 
of action. In particular, this compound inhibited both LEDGF/p75-dependent integration as well 
373 ± 72 
4.5 ± 0.5
31.3 ± 0.9
59.1 ± 3.4
!  
KF114
N
O
OH
O
FML_05 Salt
!  
KF112
N
SO2
O
OH
O
FML_3
!  
KF115
N
O
ONa
O
FML_6Salt
O
!  
KF113
N
O
ONa
O
FML_04 Salt
O
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as LEDGF/p75-independent 3’-processing activity of IN (Figure 9 and Table 6). Furthermore, 
KF113 induced aberrant IN multimerization (Figure 10), which could explain its ability to inhibit 
LEDGF/p75-independent 3’-processing activity of IN (Table 6). In addition, KF113 was able to 
inhibit IN-LEDGF/p75 binding (Figure 11). Such a multimodal mechanism of action of this 
compound is reminiscent to the mechanism of action of quinoline-based compounds, such as  
BI-B2 (9). Indeed, the x-ray crystallography studies conducted by Dr. Feng have revealed that 
KF113 binds at the IN dimer interface in the principal LEDGF/p75 binding pocket (Figure 12). 
Therefore, this compound is able to both promote aberrant IN multimerization by bridging 
between two IN subunits as well as inhibit binding of LEDGF/p75 to the IN dimer interface.   
Table 6: IC50 values of KF113 compound.  
!  
Figure 9. The dose response curve inhibiting LEDGF/p75-dependent integration by KF113. 
Compound IC50 for LEDGF/p75 
dependent 
Integration
IC50 for LEDGF/p75 
independent   
3’-proc.  activity
IC50 for aberrant IN 
multimerization
IC50 for IN-LEDGF/
p75 Binding
 KF113 4.5 ± 0.5 3.2 ± 0.5 19.7 ± 2.5 28.7 ± 3.2
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[KF113] µM 
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Figure 10. The dose response curve for KF113 promoting aberrant multimerization. 
Figure 11. The dose response curve for KF113 inhibiting IN binding to LEDGF/p75. 
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[KF113] µM 
[KF113] µM 
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Figure 12. Crystal structure of KF113 bound to the catalytic core domain of IN (determined by 
Dr. Feng). 
Indole-based compounds are potent with respect to the A128T IN mutant that confers 
resistance to quinoline-based ALLINIs. 
I have next assayed activities of KF113 with respect A128T IN. It has previously been shown 
that A128T IN exhibits remarkable (~1000-fold) resistance to archetypal quinolone-based BI-B2 
(9). In sharp contrast, KF113 inhibited both wild type and the A128T mutant INs with similar 
IC50 values (Figures 13 and 14). Therefore, while indole-based KF113 binds to the same pocket 
as quinolone-based ALLINIs, the structural difference between these two classes of compounds 
allows the indole-based KF113 to retain its activity with respect to A128T IN. 
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Figure 13. Dose response curves for KF113 promoting aberrant multimerization of WT (black 
squares) and A128T (red circles) INs. 
!  
Figure 14. Dose response curves for KF113 inhibiting 3’-processing activity of WT (black 
squares) and A128T (red circles) INs. 
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[KF113] µM 
[KF113] µM 
Discussion 
The HTRF-based assays are instrumental for dissecting the mode of action of new analogues of 
ALLINIs. Current quinolone-based ALLINIs, such as archetypal BI-B2, allosterically cause both 
aberrant IN multimerization and inhibition of IN-LEDGF/p75 binding, and have shown to be 
promising candidates for development as novel integrase-inhibiting antiretroviral therapy. Yet 
various mutations, including the A128T mutation, in the integrase catalytic core domain has led 
to resistance of IN to these compounds. Therefore, we have been investigating a new class of 
indole-based compounds. It was discovered in silico that these analogues would maintain a 
binding mode similar to BI-B2, but also orient the indole-based structures in a way that they 
could still work effectively against the A128T mutation. These initial findings prompted Dr. 
Fuchs to synthesize the indole-based compounds by modifying known structures of quinoline-
based ALLINIs. I initially examined six indole-based derivatives using the LEDGF/p75 
dependent integration assay. The compound called KF113 was the most active with an IC50 value 
of 4.5 µM. Therefore, I selected this compound for further analysis and found that KF113 
induces IN multimerization with an IC50 value of 19.7 µM and inhibits IN-LEDGF/p75 binding 
with an IC50 value of 28.7 µM, suggesting that similarly to the quinoline-based compounds, 
indole-based inhibitors exhibit a multimodal mechanism of action. However, unlike quinoline-
based BI-B2, KF113 remained active when tested with the mutant IN A128T. Therefore, the 
indole-based compounds present promising leads for development of new types of allosteric IN 
inhibitors.  
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